NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

Novo Nordisk (NOVO_B) is expected to report a 19.5% revenue rise to DKK78.08 billion and earnings per share of DKK6.11 for Q1 2025, with results due May 7.

The FDA has accepted Novo Nordisk's application for its daily oral Wegovy for weight loss, with a decision expected this year, potentially marking a first in oral GLP-1 medications.

CVS Health will continue to reimburse Novo Nordisk's obesity drug Wegovy, while it has dropped Eli Lilly's Zepbound from its reimbursement coverage following negotiations.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.